ArticleNanomedicine (London, England)2015
Arg-Gly-Asp-D-Phe-Lys peptide-modified PEGylated dendrimer-entrapped gold nanoparticles for targeted computed tomography imaging of breast carcinoma.
Article in Nanomedicine (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 26 citations in OpenAlex.
- Emerging nanoparticle-based x-ray imaging contrast agents for breast cancer screening.Nanomedicine (London, England) · 2025Review
- Targeting Ultrasmall Gold Nanoparticles with cRGD Peptide Increases the Uptake and Efficacy of Cytotoxic Payload.Nanomaterials (Basel, Switzerland) · 2022Article
- Integrin-Targeting Peptides for the Design of Functional Cell-Responsive Biomaterials.Biomedicines · 2020Review
- Development of nanoparticle-based optical sensors for pathogenic bacterial detection.Journal of nanobiotechnology · 2017Review
- A review of molecular imaging of atherosclerosis and the potential application of dendrimer in imaging of plaque.International journal of nanomedicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
Abstract
aimTo investigate cyclo (Arg-Gly-Asp-D-Phe-Lys) peptide (RGD)-modified PEGylated dendrimer-entrapped gold nanoparticles (PEGylated Au DENPs-RGD) for targeted computed tomography (CT) imaging of breast carcinomas. MATERIALS &
methodsPEGylated Au DENPs-RGD were synthesized and characterized. Then, the PEGylated Au DENPs-RGD for targeted CT imaging were investigated using the MDA-MB-435 cell line, an integrin-rich breast carcinoma cells, and mice with MDA-MB-435 xenograft tumors. Finally, silver enhancement staining and integrin αvβ3 immunohistochemistry of the tumors were performed.
resultsThe synthesized PEGylated Au DENPs-RGD were spherical, water dispersible and biocompatible nanoprobes with a gold nanoparticle core size of 2.8 nm. Due to the presence of the Au nanoparticles, the PEGylated Au DENPs-RGD displayed a higher x-ray attenuation intensity than Omnipaque at the same Au or I concentrations. The conjugated RGD ligand can specifically identify and target overexpressed integrin receptors on MDA-MB-435 cells. After intravenous injection, these nanoprobes accumulated in the targeted area of mice with MDA-MB-435 xenograft tumors, which enabled the tumor to be detected by CT imaging. The histological results confirmed the imaging results.
conclusionThe PEGylated Au DENPs-RGD can be used as targeted nanoprobes with good biocompatibility for targeted CT imaging and diagnosis of integrin-positive tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.